BridgeBio Pharma Inc. Up 77% Following Positive Results from Phase 2 Cohort 5 of Infigratinib

You may also like...

• 

  Trezor already controls its silicon chip supply chain

• 

  Rogers-Shaw deal deadline pushed back – again – as minister mulls final decision

• 

  5-Star Technology and Software Provider: Entries are now open